Skip to content
Educational information only. Not medical advice. We sell nothing and take no affiliate money.
By /
Peptide (copper complex)Limited humanNot FDA approved

GHK-Cu

Glycyl histidyl lysine copper (copper tripeptide)

Last reviewed October 27, 2026 · 25 sources · Written for general readers · Compare with another compound →

The bottom line

GHK-Cu is a small copper carrying peptide that occurs naturally in human blood. It has a long history in skin care and a handful of small cream studies suggesting modest skin benefits, but 2024 to 2026 reviews call the human evidence sparse and below modern standards.[1][2][3] A copper peptide wound gel looked good in an early diabetic foot ulcer trial but did no better than placebo in larger trials of 511 people.[4][5] There are no human trials of injected GHK-Cu, FDA says human safety data for injection are limited, and FDA plans to ask its advisers about it before the end of February 2027.[6][7]

Where the evidence stands

What it is

GHK is a tiny peptide made of three amino acids, glycine, histidine and lysine, that binds copper. The copper bound form is called GHK-Cu.[1] It was first identified in human serum in the 1970s, and reviews describe it in plasma, saliva and urine, with blood levels falling by more than half between age 20 and age 60.[8][9][11]

It is a common ingredient in creams and serums sold as cosmetics. Cosmetics do not need FDA approval before sale, but a product that claims to treat disease or change the body's structure, such as regenerating cells, is legally a drug.[20]

In the 1990s a company tested a copper peptide gel as a prescription drug for diabetic foot ulcers. It failed its large trials and was never approved.[5] In 2026 a small Phase 2 trial of a GHK-Cu skin gel for fresh wounds began recruiting in China, which is why we list it as investigational.[18]

Injectable GHK-Cu is a separate issue. FDA handles injected use differently from creams because of safety concerns.[6][21]

One 2026 review noted that about 35% of the primary GHK-Cu studies it covered list Pickart or Margolina, who work in the skin product field, as authors.[19][11]

Name
GHK-Cu (Glycyl histidyl lysine copper (copper tripeptide))
Other names
copper peptide, prezatide copper, Cu GHK
Type
Peptide (copper complex)
Sequence
GHK

What it does in the body

GHK is a natural chain of three amino acids (glycine, histidine and lysine) found in human blood plasma, saliva and urine. It was identified in 1977 as a growth promoting factor in human serum.[8][9] It grabs copper tightly, and the copper bound form is GHK-Cu. Its main actions in lab studies are on fibroblasts, the cells that build collagen, and on the enzymes that break down and rebuild tissue during repair.[9][10]

This is the biology, area by area. A change measured in the body, like a higher blood level, does not always mean a person feels a benefit. The claims check below covers that.

Skin and hair

Measured in people

In a small pilot study, skin samples showed new collagen in 70% of 20 women using a GHK-Cu cream on the thigh, compared with 50% for vitamin C and 40% for retinoic acid creams, with no placebo group.[1] One double blind study in women found 55.8% less wrinkle volume after 8 weeks than a plain serum.[11] A 2026 review found a 13 person study after laser skin resurfacing was negative on objective measures, and an 18 person eyebrow study reported better hair results.[3] These are measured skin changes, but the studies are small and often industry run.[12]

Wounds and tissue repair

Measured in people

In rats with poorly supplied skin wounds, wound area shrank 64.5% with a copper peptide gel by day 13, versus 45.6% with plain gel and 28.2% with no treatment.[13] In people with diabetic foot ulcers, an early trial looked positive, but two larger trials in 511 people found the gel no better than placebo.[4][5][14] So the healing effect seen in animals did not hold up in the one large human test.

Collagen and tissue remodeling

Seen in animals

Change the level for Collagen and tissue remodeling from lab to animals; the sentence text can stay as written. In rats with small wound chambers under the skin, it kept some tissue remodeling enzymes, called metalloproteinases, active for longer in late healing.[10] In dogs, wounds injected with a copper peptide had the most type I collagen, the main strong collagen, at day 14.[15]

Absorption through skin

Lab finding

On donor human skin in a lab chamber, copper from a GHK-Cu solution passed through the skin over 48 hours, and a similar amount stayed behind in the skin as a reservoir.[16] That study measured copper, not the intact peptide. A 2024 review concluded GHK-Cu gets into skin fairly well for a peptide, but that formulas vary a lot.[2]

Gene activity

Lab finding

Using gene databases built from human cells in a dish, supporters report that GHK shifted the activity of thousands of human genes, about 31% of genes by at least half, toward patterns linked with repair.[11][9] These are readings from cells, not measurements in a living person.

Lungs

Seen in animals

In mice with chemically triggered lung injury, GHK reduced lung damage and inflammation signals.[11] No human lung study exists.

Brain and mood

Seen in animals

Rat and mouse studies report more nerve regrowth inside collagen tubes, more exploring and less freezing in anxiety tests, and slower reactions to heat pain.[11] Blood GHK falls with age, by about 60% between age 20 and age 60 in one estimate, which supporters link to aging, but this has not been tested as a cause.[17]

How it works

Most of what is known about how GHK-Cu works comes from cell and gene studies.

  • In lab studies it raised production of collagen, elastin and other building blocks of skin, and supported fibroblasts, the cells that make them.[11][9]
  • Its supporters point to gene data suggesting it turns many repair and protection genes up or down.[11]
  • In rats with small wound chambers placed under the skin, GHK-Cu changed the timing of enzymes that break down and remodel tissue during healing.[10]
  • Peptides are large molecules for skin, and how deep they get depends on the formula and the condition of the skin. Getting peptides into the deeper skin layer is still an unsolved problem.[1][2]
  • A 2026 review warned that studies often do not say how much copper is actually bound to the peptide, so different products may not behave the same.[3]

Gene and cell findings are a long way from proof that a cream or injection changes skin in a meaningful way.

What the research shows

We keep animal and human evidence apart. A result in animals is a reason to study something in people, not proof that it works in people.

Animal and lab studies

Wound healing in animals looks promising

  • Studies in rabbits, rats, pigs and mice reported better wound healing, including in diabetic rats and in animals whose healing was slowed by cortisone.[11]
  • In 24 rats with poorly supplied skin wounds treated daily for 13 days, wounds shrank 64.5% with a copper peptide gel, 45.6% with plain gel and 28.2% with no treatment.[13]
  • In 12 dogs with paw pad wounds, wounds injected with a copper peptide had the most strong type I collagen at day 14.[15] In rats, a collagen dressing containing GHK raised collagen about ninefold in healthy animals.[11]
  • In rats with implanted wound chambers, GHK-Cu kept some tissue remodeling enzymes active for longer during the later stages of healing.[10]
  • In mice with chemically triggered lung injury, GHK reduced lung damage and inflammation signals.[11]
  • Rodent studies also reported more nerve regrowth inside collagen tubes, less anxious behavior and less sensitivity to heat pain.[11]

Limit: The wound results come from animals, and the one large human wound program failed.[5]

Human studies

Small cosmetic cream studies, a failed wound gel, no injection trials

  • In a small pilot study, 20 women applied a GHK-Cu cream, a vitamin C cream or a retinoic acid cream to the thigh. Skin samples showed new collagen in 70% of the GHK-Cu group, 50% of the vitamin C group and 40% of the retinoic acid group. There was no placebo group.[1]
  • Two 12 week studies of a face cream and an eye cream in 71 and 41 women with sun damaged skin reported thicker, firmer skin and fewer fine lines. The eye cream was compared with a placebo cream and a vitamin K cream. Both were presented at a conference rather than published as full papers.[1][11]
  • A 12 week study in 67 women using a GHK-Cu cream reported improved sun damaged skin and thicker skin layers on skin samples. The review gives no numbers.[1]
  • A randomized double blind study in women found 55.8% less wrinkle volume and 32.8% less wrinkle depth after 8 weeks of a GHK-Cu serum than with a plain serum.[11]
  • A 13 person study of GHK-Cu after carbon dioxide laser resurfacing found no benefit on objective measures, while an 18 person split face eyebrow study published in 2026 reported better cosmetic hair results.[3]
  • An early randomized, evaluator blinded trial of a copper peptide gel in people with diabetic foot ulcers reported median closure of plantar ulcers of 98.5% versus 60.8% with a plain gel. Infections were less common when the gel was started right after wound cleaning, 7% versus 34%.[4]
  • Two larger Phase 3 trials then enrolled 511 people with diabetic foot ulcers at 30 centers, testing two strengths of the gel against placebo. The gel was no better than placebo.[14][5]
  • A Phase 2 trial that started in February 2026 in China plans to enroll 60 people, each with two small punch biopsy wounds, one treated with a GHK-Cu skin gel and one with a plain gel, and to measure days to full skin closure. It has no results yet.[18]
  • We found no human trial of injected GHK-Cu, and FDA says there are limited human data on its safety by injection.[6]
  • Two 2024 to 2026 reviews concluded that human trials are few, small and mostly about cosmetic creams, and that results often come from mixed formulas with other active ingredients.[2][12]

Limit: The cream studies were small, often used formulas with other active ingredients, and many never appeared in peer reviewed journals.[1][3]

Claims check

The most common claims about this compound, and what studies actually found. Verdicts rate the evidence, not whether you should use it.

Reduces wrinkles and firms skin

Mixed results

Two 12 week cream studies in 71 and 41 women with sun damaged skin reported thicker, firmer skin and fewer fine lines, and the eye cream beat a placebo cream, but both appeared only as conference abstracts.[11] One randomized double blind study in women found 55.8% less wrinkle volume after 8 weeks than a plain serum, and 31.6% less than a comparison peptide serum.[11] A 2024 review called clinical studies surprisingly scarce, and a 2026 review said the evidence does not meet current quality standards.[2][3]

Builds collagen in the skin

Mixed results

In a small pilot study, 20 women applied a GHK-Cu cream, a vitamin C cream or a retinoic acid cream to the thigh. Skin samples showed new collagen in 70%, 50% and 40% of each group. There was no placebo group.[1] Another 12 week study in 67 women reported thicker skin layers on skin samples, without numbers in the review.[1]

Heals wounds and skin ulcers

No benefit in trials so far

An early randomized trial of a copper peptide gel in diabetic foot ulcers reported median closure of plantar ulcers of 98.5% with the gel versus 60.8% with a plain gel, along with fewer infections.[4] Two larger Phase 3 trials then enrolled 511 people at 30 centers and tested two strengths against placebo. The gel was no better than placebo.[14][5] A new Phase 2 trial in 60 people with small punch biopsy wounds began in 2026 and has no results yet.[18]

Regrows hair

Mixed results

A cosmetic peptide review mentions a hair transplant study that reported improvement with a copper peptide product, but gives no design, size or numbers.[1] A 2026 review describes an 18 person split face eyebrow study with positive cosmetic hair results, without clear detail on what form of GHK-Cu was used.[3] No controlled trial in scalp hair loss turned up.

Repairs skin after laser or cosmetic procedures

Mixed results

A 2026 review found a 13 person study of GHK-Cu after carbon dioxide laser resurfacing that was negative on objective measures.[3] Another 2026 review argues microneedle delivery has never been tested in a properly sized human trial.[19]

Speeds healing all over the body when injected

Only in animals

In mice, rats and pigs, GHK-Cu given into the body offset the slow healing caused by cortisone, a finding reported in a patent. Rodent studies also report less lung injury and better nerve regrowth.[11] No trial has tested injected GHK-Cu in people, and FDA says human safety data for injection are limited.[6]

Resets aging genes

Only in animals

Using gene databases built from human cells in a dish, supporters report that GHK changed the activity of about 31% of human genes by at least half, which they read as nudging genes toward a healthier pattern.[11] These are lab readings from cells, not measurements of any change in a living person.

Calms anxiety and pain

Only in animals

Rat and mouse studies report more exploring and less freezing in anxiety tests and slower reactions to heat pain.[11] The main review describes no human study of these effects.[11]

Known risks and side effects

  • Injection is largely untested. FDA says injected GHK-Cu may trigger immune reactions from clumped peptide and impurities, and human safety data are limited.[6]
  • Unregulated vials. FDA's compounding category for GHK-Cu now covers only routes that are not injected, so injectable vials sold online fall outside it and have no FDA quality review.[21]
  • Products are not standardized. A 2026 review found that most studies and products do not report how much copper is bound or free, which matters for both effect and safety.[3]
  • Cream claims can outrun the evidence. Many cosmetic peptide studies are small, short, industry sponsored, test mixed formulas and are never published in scientific journals.[1][12]
  • Drug claims cross a legal line. A product that claims to restore hair growth or regenerate cells is legally a drug, not a cosmetic, and needs FDA approval.[20]

Regulatory status

Today: GHK-Cu is not an approved drug. A small Phase 2 trial of a GHK-Cu skin gel for fresh wounds is recruiting.[18] For compounding, FDA lists GHK-Cu for routes other than injection in category 1, while injectable GHK-Cu is listed among substances previously in category 2 whose nominations were withdrawn.[21][6] FDA plans an advisory committee meeting on GHK-Cu before the end of February 2027.[7] On October 28, 2026 HHS filed an interim policy easing enforcement for compounding of six other peptides, but GHK-Cu is not among them.[22][23][24] GHK-Cu is not named on the 2027 World Anti Doping Agency list.[25] Creams with GHK-Cu are sold as cosmetics, which need no FDA approval unless they make drug claims.[20]

  1. Two Phase 3 trials of a copper peptide wound gel in 511 people with diabetic foot ulcers show it works no better than placebo.[14][5]
  2. A Phase 2 trial of a GHK-Cu skin gel on small biopsy wounds starts recruiting in China.[18]
  3. FDA removes GHK-Cu from category 1 after its nominators withdrew, and lists injectable GHK-Cu among withdrawn nominations no longer in category 2.[21][6]
  4. One nominator clarified it meant to withdraw only the injectable route, so FDA returned GHK-Cu for routes other than injection to category 1.[21]
  5. HHS files an interim compounding policy for six peptides. GHK-Cu is not included.[22][24]
  6. FDA plans to ask its Pharmacy Compounding Advisory Committee whether GHK-Cu belongs on the 503A bulks list.[7]

Sources

  1. Schagen SK. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics. 2017;4(2):16. doi 10.3390/cosmetics4020016
  2. Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts. 2024;15:30071. PMID 39963574
  3. Mateescu DM, Gavrilescu DM, Mincioaga RI, et al. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics. 2026;18(9):1077. PMID 42797253
  4. Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair Regen. 1994;2(4):259-269. doi 10.1046/j.1524-475X.1994.20406.x
  5. The Pharma Letter. ProCyte's lead product no better than placebo. October 1994. Trade news
  6. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of April 22, 2026. FDA category 2 page
  7. U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee (meeting planned before the end of February 2027). Content current as of April 15, 2026. FDA advisory committee page
  8. Schlesinger DH, Pickart L, Thaler MM. Growth-modulating serum tripeptide is glycyl-histidyl-lysine. Experientia. 1977;33(3):324-325. doi 10.1007/bf02002806
  9. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. PMID 26236730
  10. Simeon A, Monier F, Emonard H, et al. Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. J Invest Dermatol. 1999;112(6):957-964. PMID 10383745
  11. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi 10.3390/ijms19071987
  12. Yi KH, et al. Peptides in Aesthetic Dermatology: Classification, Fibroblast-Centered Mechanisms, Delivery Technologies, and Clinical Evidence. Life (Basel). 2026;16(10):1660. PMID 42942246
  13. Canapp SO Jr, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg. 2003;32(6):515-523. PMID 14648529
  14. BioCentury. Iamin gel peptide copper compound completed two Phase III trials. October 3, 1994. Trade news
  15. Swaim SF, et al. Effect of locally injected medications on healing of pad wounds in dogs. Am J Vet Res. 1996;57(3):394-399. PMID 8669775
  16. Hostynek JJ, Dreher F, Maibach HI. Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy. Inflamm Res. 2010;59(11):983-988. PMID 20703511
  17. Dou Y, et al. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. 2020;2(1):58-61. PMID 35083444
  18. ClinicalTrials.gov. A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Split-Wound Study of Topical GHK-Cu (NCT07437586). Sponsor Hudson Biotech. Record last updated February 2026. NCT07437586
  19. Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9(3):269-293. PMID 42787770
  20. U.S. Food and Drug Administration. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?). FDA cosmetics guidance
  21. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026. FDA 503A bulks list
  22. U.S. Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Docket HHS-OASH-2026-0496. Filed for public inspection October 28, 2026; Federal Register document 2026-22192, publication October 30, 2026. FR Doc. 2026-22192
  23. U.S. Department of Health and Human Services. 503A Peptide Enforcement Discretion Policy, Appendix B: peptide identity and route limits. October 2026. HHS policy appendix
  24. Steinzor P. 5 Things to Know About HHS's Interim Peptide Compounding Policy. The American Journal of Managed Care. October 29, 2026. Policy coverage
  25. World Anti-Doping Agency. The 2027 Prohibited List. Comes into effect 1 January 2027. WADA 2027 List
Medical disclaimer

This page is educational information only. It is not medical advice and does not replace care from a licensed medical provider. Do not use this page to decide whether to take any substance. Talk to a licensed medical provider first.

Found an error or a newer study? We correct pages fast.

Report a correction →
Scroll to Top